ADULT T-CELL LEUKEMIA/LYMPHOMA
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 16 to 60
Trial IDs: GC P#05.01.020, NCI-2016-01518, NCT02730299
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: 95-024, NCI-2017-00824, MSKCC-95024, NCI-V95-0685, P30CA008748, NCT00002663
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, 9936-ALCI, H-9936, NCT00070226, NCT00671164, NCT00062868
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NCT01203722
Dasatinib in Treating Patients with Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated with Autologous Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA-180-381, NCI-2012-00767, 1203010693, 2011-203, NCT01609816
Conventional and Regulatory T Cells in Treating Patients with Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 13 to 60
Trial IDs: BMT236, NCI-2011-03025, NCT01660607
EWING SARCOMA/PNET
Combination Chemotherapy with or without Ganitumab in Treating Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1221, NCI-2014-02380, NCT02306161
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
Talazoparib and Temozolomide in Treating Younger Patients with Refractory or Recurrent Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 30 years
Trial IDs: ADVL1411, NCI-2014-00804, NCT02116777
Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: ADVL1412, NCI-2014-01222, NCT02304458
Pexidartinib in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
GASTROINTESTINAL STROMAL TUMOR (GIST)
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AB04030, NCI-2011-02630, NCT00812240
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AB11002, NCI-2012-01957, NCT01694277
Surgery or Non-surgical Management in Treating Patients with Intra-abdominal Cancer and Bowel Obstruction
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: S1316, NCI-2014-01497, SWOG/S1316, NCT02270450
Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ARO-012, NCI-2016-01344, NCT02847429
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
Binimetinib and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-162, NCI-2013-02281, NCT01991379
PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX121-01, NCI-2015-00669, NCT02401815
GRAFT-VERSUS-HOST DISEASE
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
Status: Active
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 471501, NCI-2016-01887, NCT02956122
Tacrolimus and Methotrexate with or without Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host-Disease in Patients with Hematological Malignancy Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase III
Type: Supportive care
Age: 70 and under
Trial IDs: CASE 6Z13, NCI-2013-01800, NCT01951885
Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1331, NCI-2014-00631, COG-AALL1331, NCT02101853
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 65
Trial IDs: BMTCTN1301, NCI-2015-01813, U01HL069294, NCT02345850
A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Status: Active
Phase: Phase III
Type: Treatment
Age: 2 months to 17 years
Trial IDs: MSB-GVHD001, NCI-2015-00354, NCT02336230
UVADEX(R) and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 21
Trial IDs: TKS-2014-001, NCI-2015-01646, NCT02524847
Safety Follow-up of Treatment With Remestemcel-L in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Status: Active
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Age: 2 months to 17 years
Trial IDs: MSB-GVHD002, NCI-2016-00303, NCT02652130
Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 12 and over
Trial IDs: PCYC-1140-IM, NCI-2017-00036, NCT02959944
NEUROBLASTOMA
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
Status: Active
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 471501, NCI-2016-01887, NCT02956122
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 months and under
Trial IDs: ANBL1232, NCI-2014-00677, NCT02176967
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 365 days to 30 years
Trial IDs: ANBL1531, NCI-2016-01734, NCT03126916
OPT-821 with Vaccine Therapy and Beta-Glucan in Treating Younger Patients with High-Risk Neuroblastoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 21 and under
Trial IDs: 05-075, NCI-2009-01362, NCT00911560
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Humanized Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with Relapsed or Refractory High-Risk Neuroblastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 1
Trial IDs: 12-230, NCI-2013-00007, NCT01757626
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
WEE1 inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1312, NCI-2014-00547, NCT02095132
Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 21 and under
Trial IDs: NMTRC010, NCI-2015-01871, NCT02139397
LUNG CANCER
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Status: Active
Phase: Phase IV
Type: Treatment
Age: 70 and over
Trial IDs: 1200.209, NCI-2016-00277, NCT02514174
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin(R) in Unresectable Peripheral Lung Cancer
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CLI-PHO1601, NCI-2017-00430, NCT02916745
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, S1400I, NCT02154490
Quercetin in Preventing Venous Thromboembolic Events in Patients with Pancreatic Cancer That is Metastatic or Cannot Be Removed by Surgery, Stage III-IV Non-small Cell Lung Cancer, or Stage IV Colorectal Cancer
Status: Active
Phase: Phase III, Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 14-114, NCI-2015-01705, NCT02195232
Counseling Sessions in Reducing Tobacco Dependence in Participants Undergoing Lung Cancer Screening
Status: Active
Phase: Phase III, Phase II
Type: Behavioral study
Age: 55 to 80
Trial IDs: 2011-541, NCI-2016-01236, NCT02267096
Afatinib Dimaleate with or without Cetuximab in Treating Patients with Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1403, NCI-2014-02405, BI 1200.124, NCT02438722
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: LF-0208, NCI-2009-01425, NCT00706862
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
Status: Active
Phase: Phase III
Type: Diagnostic
Age: 18 and over
Trial IDs: AMI-2008-01, NCI-2014-02587, NCT00882609
Standard or Accelerated Hypofractionated Image-Guided Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer and Poor Performance Status
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: STU 052011-093, NCI-2013-00783, NCT01459497
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TV1011-LC-303, NCI-2015-00116, 2012-002447-14, NCT01630733
Patient Navigation Intervention in Improving Surgery Rates in African Americans with Early Stage Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Educational/Counseling/Training, Supportive care
Age: 21 and over
Trial IDs: 01414, NCI-2014-02559, 101487, WF-01414, NCT01885455
SOFT TISSUE SARCOMA, ADULT
Radiation Therapy with or without Combination Chemotherapy or Pazopanib Hydrochloride before Surgery in Treating Patients with Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 and over
Trial IDs: ARST1321, NCI-2014-01340, NCT02180867
Selinexor in Advanced Liposarcoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 12 and over
Trial IDs: KCP-330-020, NCI-2016-00746, 2015-003594-14, NCT02606461
Combination Chemotherapy with or without Temsirolimus in Treating Patients with Intermediate Risk Rhabdomyosarcoma
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 40 and under
Trial IDs: ARST1431, NCI-2015-01644, NCT02567435
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients With Synovial Sarcoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 4 to 55
Trial IDs: ADP 04511, NCI-2015-00410, NCI-2013-01481, UPCC 04511, NCT01343043
Image-Guided Intensity-Modulated Proton or Photon Beam Radiation Therapy with Boost in Treating Patients with Primary or Locally Recurrent Soft Tissue Sarcoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-100, NCI-2012-01931, NCT01659203
Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-104, NCI-2013-01735, UPCI 12-104, NCT01879085
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105SAR101, NCI-2014-00305, NCT01975519
THYROID CANCER
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Status: Active
Phase: Phase II, Phase I
Type: Supportive care
Age: Not specified
Trial IDs: SAL 2012-0584, NCI-2014-00167, NCT01739634
Sapanisertib in Treating Patients with Newly Diagnosed or Refractory/Metastatic Anaplastic Thyroid Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-223, NCI-2015-01607, NCT02244463
A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX120-03, NCI-2015-00720, NCT02428712
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: SCRX001-006, NCI-2016-01071, NCT02709889
Biomarkers in Predicting Response in Patients with Locally Advanced Thyroid Cancer Receiving Vemurafenib before Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0471, NCI-2012-02171, 00000363, NCT01709292
Vaccine Therapy in Treating Patients with Recurrent or Metastatic Medullary Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0095, NCI-2013-01587, 1301-1199, GI-6207, GI-6207-02, P11934, RD-13-I-10, NCT01856920
Calcitriol before Surgery in Preventing Calcium Loss in Patients Undergoing Thyroidectomy
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: TC-P2-CALCITRIOL, NCI-2014-00962, NCT01868750
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients with Primary or Metastatic Gastrointestinal or Pancreatic Neuroendocrine Tumors
Status: Active
Phase: Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: 13-C-0193, NCI-2014-02318, 335154, NCT01967537
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Cabozantinib-S-Malate as First-Line Therapy in Treating Patients With Radioiodine-Refractory Thyroid Cancer That is Metastatic or Cannot Be Removed By Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 28313, NCI-2014-00171, 818408, UPCC 28313, NCT02041260
Cabozantinib-S-Malate in Treating Patients with Refractory Thyroid Cancer
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9312, NCI-2013-00554, 2012C0101, OSU 12154, RU241210I, NCT01811212
Vaccine Therapy in Treating Patients with Recurrent or Metastatic Medullary Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0095, NCI-2013-01587, 1301-1199, GI-6207, GI-6207-02, P11934, RD-13-I-10, NCT01856920
Calcitriol before Surgery in Preventing Calcium Loss in Patients Undergoing Thyroidectomy
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: TC-P2-CALCITRIOL, NCI-2014-00962, NCT01868750